Denise M. Wolf
Impact in
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Cancer Genomics and Diagnostics 24
- Breast Cancer Treatment Studies 10
- Oncology 38
- Cancer Immunotherapy and Biomarkers 13
- Cancer Cells and Metastasis 9
- HER2/EGFR in Cancer Research 8
- PARP inhibition in cancer therapy 6
- Co-authors
- Adam P. Arkin (8 shared papers)Christopher V. Rao (1 shared paper)Laura van ‘t Veer (39 shared papers)Miranda L. Broz (3 shared papers)Matthew F. Krummel (3 shared papers)Mikhail Binnewies (3 shared papers)Amanda E. Nelson (3 shared papers)Vijay V. Vazirani (2 shared papers)
- Journals
- npj Breast Cancer (7 papers)Clinical Cancer Research (7 papers)Breast Cancer Research and Treatment (7 papers)Cancer Cell (6 papers)Breast Cancer Research (4 papers)
- Partner nations
- United StatesNetherlandsBelgium
In The Last Decade
Denise M. Wolf
87 papers receiving 14.4k citations
Denise M. Wolf's Hit Papers
Peers
Comparison fields: 5 of 161
- Cancer Research 3.6k
- Oncology 4.9k
- Immunology 3.1k
- Molecular Biology 6.3k
- Pulmonary and Respiratory Medicine 1.9k
Countries citing papers authored by Denise M. Wolf
This map shows the geographic impact of Denise M. Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denise M. Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denise M. Wolf more than expected).
Fields of papers citing papers by Denise M. Wolf
This network shows the impact of papers produced by Denise M. Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denise M. Wolf. The network helps show where Denise M. Wolf may publish in the future.
Co-authors
The 25 scholars most cited alongside Denise M. Wolf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 89 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics Hit paper breakdown → | 2018 | 2602 |
| 2 | Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer Hit paper breakdown → | 2018 | 1720 |
| 3 | Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin Hit paper breakdown → | 2014 | 1158 |
| 4 | Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity Hit paper breakdown → | 2014 | 1013 |
| 5 | Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma Hit paper breakdown → | 2016 | 834 |
| 6 | A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments Hit paper breakdown → | 2018 | 816 |
| 7 | Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas Hit paper breakdown → | 2018 | 810 |
| 8 | Control, exploitation and tolerance of intracellular noise Hit paper breakdown → | 2002 | 789 |
| 9 | The Immune Landscape of Cancer Hit paper breakdown → | 2019 | 449 |
| 10 | 2011 | 379 | |
| 11 | 2020 | 355 | |
| 12 | 2011 | 282 | |
| 13 | Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial Hit paper breakdown → | 2021 | 258 |
| 14 | Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies Hit paper breakdown → | 2022 | 241 |
| 15 | 2018 | 230 | |
| 16 | 2005 | 226 | |
| 17 | 2003 | 217 | |
| 18 | Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy Hit paper breakdown → | 2023 | 137 |
| 19 | 2014 | 124 | |
| 20 | 2019 | 112 |
About Denise M. Wolf
Denise M. Wolf is a scholar working on Cancer Research, Oncology, Molecular Biology, Immunology and Genetics, having authored 89 papers that have together received 14.7k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (24 papers), Cancer Immunotherapy and Biomarkers (13 papers), Breast Cancer Treatment Studies (10 papers), Cancer Cells and Metastasis (9 papers), HER2/EGFR in Cancer Research (8 papers), Bacterial Genetics and Biotechnology (6 papers), Evolution and Genetic Dynamics (6 papers) and PARP inhibition in cancer therapy (6 papers). The work is most often cited by research in Cancer Research (3.6k citations), Oncology (4.9k citations), Immunology (3.1k citations), Molecular Biology (6.3k citations) and Pulmonary and Respiratory Medicine (1.9k citations). Denise M. Wolf has collaborated with scholars based in United States, Netherlands and Belgium. Frequent co-authors include Adam P. Arkin, Christopher V. Rao, Laura van ‘t Veer, Miranda L. Broz, Matthew F. Krummel, Mikhail Binnewies, Amanda E. Nelson, Vijay V. Vazirani, Dusan Bogunovic and Edward W. Roberts. Their work appears in journals such as npj Breast Cancer, Clinical Cancer Research, Breast Cancer Research and Treatment, Cancer Cell and Breast Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.